SCC641
HCI-EC-23 Human Endometrial Cancer Cell Line
Synonyme(s) :
HCI-EC-23 Human Endometrial Cancer Cell Line
About This Item
Produits recommandés
Source biologique
human
Niveau de qualité
Conditionnement
vial of ≥1 x 10^6 vial (viable cells per vial)
Fabricant/nom de marque
Millipore
Technique(s)
cell culture | mammalian: suitable
Conditions d'expédition
liquid nitrogen
Température de stockage
−196°C
Application
- Each vial contains > 1X106 viable cells.
- Cells are tested negative for infectious diseases by Essential CLEAR Panel by Charles River Animal Diagnostic Services.
- Cells are verified to be of human origin and negative for interspecies contamination from human, rat, Chinese hamster, Golden Syrian hamster, and nonhuman primate (NHP) as assessed by a Contamination Clear panel by Charles River Animal Diagnostic Services
- Cells are negative for mycoplasma contamination.
Caractéristiques et avantages
Description de la cible
A variety of cell lines have been created from Type I tumors such as Ishikawa cells. However, many of these cell lines have lost ERα expression and estrogen response. The limited availability of ERα expressing endometrial cell lines limits the variety of genetic backgrounds for understanding endometrial cancer. Patient derived xenografts (PDX) have increased the capability to produce hormone-responsive models but lack some of the benefits of a cell line model.
The HCI-EC-23 human endometrial cancer cell line was derived by generating a PDX cell line in a mouse model. Cells from an endometrial carcinoma sample were injected into immunodeficient mice and grown in the mouse model before being harvested. PDX samples were dissociated, grown on collagen coated plates and selected for predominantly human (99%) cells which became the HCI-EC-23 cell line. These cells retain ER expression and estrogen-responsiveness in vitro and in vivo. The cell line contains important mutations relevant to endometrial carcinomas including mutations at PTEN, PIK3CA, ARID1A, CTCF, and ATM, but remains wild-type for PIK3R1, CTNNB1, KRAS and TP53. Progesterone receptor genes and estrogen receptor genes also remain wild-type.
Estrogen responsiveness was tested in the HCI-EC-23 cell line by transfecting cells with a luciferase reporter under control of tandem estrogen response elements and treating cells with E2. HCI-EC-23 cells also showed estrogen responsiveness to 4-hydroxy-tamoxifen (4OHT) treatment which is consistent with observations of endometrial response.
Source: Primary tumor was obtained from a 66-year old woman diagnosed with Grade 2 Stage 1A endometrioid endometrial carcinoma which was later cloned into a mouse PDX model. A predominantly human (99%) cell outgrowth was used to derive the HCI-EC-23 human endometrial cancer cell line.
References
1. Rush, C.M., Blanchard, Z., Polaski, J.T. et al. Characterization of HCI-EC-23 a novel estrogen- and progesterone-responsive endometrial cancer cell line. Sci Rep 12, 19731 (2022).
Stockage et stabilité
Autres remarques
Clause de non-responsabilité
Code de la classe de stockage
10 - Combustible liquids
Classe de danger pour l'eau (WGK)
WGK 2
Point d'éclair (°F)
Not applicable
Point d'éclair (°C)
Not applicable
Certificats d'analyse (COA)
Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..
Contacter notre Service technique